Keywords: teva, azilect, meets, all, endpoints, adagio, trial
Teva's Azilect meets all endpoints in ADAGIO trial
Article | 08 September 2008
Israeli drug major Teva Pharmaceuticals Industries says that Azilect (rasagiline) reached all its endpoints in a late-stage trial. The Parkinson's ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
